– USA, NY – AXIM Biotechnologies, Inc. (OTC: AXIM), an international healthcare solutions company targeting oncological and COVID-19 research, today announced the addition of Former Secretary of Veterans Affairs Peter O’Rourke to its Board of Directors.
“Peter has an impressive reputation for leading people with the highest level of professionalism and making difficult strategic decisions for the greater good,” said CEO, John Huemoeller. “As we move into new, exciting but uncharted territory of helping with the COVID-19 crisis, we believe that Peter will help us make the smartest, most efficient evaluations on our present and future operations.”
About Peter O’Rourke
O’Rourke brings more than 20 years of experience serving in senior leadership roles in the public and private sectors. He has held leadership roles in management consulting, private equity, aerospace, and operations companies with experience in sales, marketing, operations, finance, and performance improvement. He was appointed Acting Secretary of the U.S. Department of Veterans Affairs in 2018 after serving as the Chief of Staff and Executive Director for the Office of Accountability and Whistleblower Protection. Before joining the Department of Veterans Affairs, O’Rourke honorably served as a U.S. Navy enlisted Airman and an Air Force Officer and Logistician.
“In addition to AXIM’s mission to improve global cancer care, I’m confident that the Company’s newest innovation of a rapid diagnostic test measuring neutralizing antibodies will help address the COVID-19 crisis. I look forward to using my long track record of leadership experience and professional relationships to help guide AXIM to its future success,” commented O’Rourke.
O’Rourke received a Bachelor of Arts in Political Science from the University of Tennessee in Knoxville as well as a Master of Science in Logistics and Supply Chain Management from the United States Air Force’s Institute of Technology.
About AXIM Biotechnologies
Founded in 2014, AXIM Biotechnologies, Inc. is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2. AXIM’s NeuCovixTM is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis.
For more information: https://aximbiotech.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
